Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285472 | 0.79 | HRH3 (0.45) | ALDH1A1KDM4ESMN1; SMN2HRH3LSS | |
| SCHEMBL22837834 | 0.79 | KDM4E (0.43) | ALDH1A1KDM4ESMN1; SMN2HRH3LSS | |
| SCHEMBL9908278 | 0.77 | HRH3 (0.47) | ALDH1A1KDM4ESMN1; SMN2HRH3HRH1 | |
| SCHEMBL9906412 | 0.76 | KCNH2 (0.42) | ALDH1A1KDM4ESMN1; SMN2HRH3LSS | |
| SCHEMBL22837835 | 0.76 | LSS (0.47) | ALDH1A1KDM4ESMN1; SMN2HRH3LSS | |
| SCHEMBL15195574 | 0.73 | RXRA (0.41) | — | |
| SCHEMBL933238 | 0.73 | KDM4E (0.44) | ALDH1A1KDM4ESMN1; SMN2HRH3LSS | |
| SCHEMBL12359378 | 0.72 | HRH3 (0.73) | ALDH1A1KDM4ESMN1; SMN2HRH3LSS | |
| SCHEMBL25974821 | 0.71 | CHRNB2 (0.44) | KDM4EHRH3 | |
| SCHEMBL14301472 | 0.69 | KDM4E (0.44) | ALDH1A1KDM4ESMN1; SMN2HRH3LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | ALDH1A1 999/4885KDM4E 3363/4885SMN1; SMN2 4746/4885 |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | ALDH1A1 999/4885KDM4E 3363/4885SMN1; SMN2 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.